Skip to main content

Table 3 Baseline Characteristics of the COPD and healthy subjects that donated blood for the MDM eosinophil efferocytosis assays

From: COPD exacerbation severity and frequency is associated with impaired macrophage efferocytosis of eosinophils

  COPD (n = 17) Control (n = 8) P value
Male, n (%) 10 (58.8) 4 (50) 1
Age (years)* 68.05 (2.3) 54.1 (4.7) 0.006
Body mass index (kg/m 2 ) 27.17 (1.36) 33 (29–34) 0.07
Never-smokers n (%) 0 (0) 6 (75) 0.0002
Pack years smoked 42 (31–70) 13 (5–22) 0.05
COPD duration (years) 9.6 (8–13) NA NA
Exacerbations in last year 1 (1–2) NA NA
ICS dose (BDP equivalent) (mcg/day) 2000 (1600–2000) NA NA
FEV 1 % predicted, (%) 43 (5.1) 95 (85–110) <0.0001
FEV 1 post bronchodilator (L) 1.13 (0.14) 2.8 (2.5-3.8) 0.0004
Post FEV 1 /FVC (%) 48.6 (4.23) 84.08 (1.7) <0.0001
Reversibility, % 5.67 (2.17) 0.57 (-1.9-9) 0.45
Sputum Total cell count ×10 6 /g 3.3 (1.5-6.7) NA NA
Sputum neutrophils (%) 65 (40–80) NA NA
Sputum eosinophils (%) 7.3 (4.5-15) NA NA
GOLD 1, n (%) 0 (0) NA NA
GOLD 2, n (%) 7 (41.2) NA NA
GOLD 3, n (%) 5 (29.4) NA NA
GOLD 4, n (%) 5 (29.4) NA NA
Blood neutrophils (×10 9 /L) 4.66 (3.67-5.94) 3.5 (2.6-4.5) 0.03
Blood eosinophils (×10 9 /L) 0.21 (0.08-0.36) 0.15 (0.11-0.34) 0.86
CRP (mg/dl) 5 (<5-8) 5 (<5-5.75) 0.95
Bacterial colonisation, n (%) 3 (17.6) NA NA
CFU unit/ml** 6.5 (5.6-7) NA NA
MRC dyspnoea scale 3 (2–4) NA NA
SGRQ total score 54 (41–66) NA NA
CRQ total score 4.1 (3.2-5.7) NA NA
VAS cough (mm) 26 (11.5-67.5) NA NA
VAS dyspnoea (mm) 50 (36–64) NA NA
VAS sputum production (mm) 23.7 (6–63) NA NA
VAS sputum purulence (mm) 12.4 (6–62) NA NA
  1. Data presented as median (IQR) unless stated, *mean (SEM), **Geometric mean of Log data (95% CI). SEM: standard error of mean, CI: confidence interval.
  2. Abbreviations: AUC Area under the curve, BDP Beclometasone dipropionate, CFU Colony forming unit, CRQ Chronic Respiratory Questionnaire, CRP C-reactive protein, FEV1 Forced expiratory volume in 1 second, FVC Forced vital capacity, GOLD Global Initiative for Chronic Obstructive Lung Disease; ICS Inhaled corticosteroids, MRC Medical Research Council, SGRQ St George’s Respiratory Questionnaire, TCC Total cell count, VAS Visual analogue score.